1514 - Brain metastases (BM) in patients (pts) with soft tissue and bone sarcoma (sarcoma): a retrospective study of 107 pts

Date 28 September 2012
Event ESMO Congress 2012
Session Publication Only
Topics Sarcoma
Presenter Angela Cioffi
Authors A. Cioffi1, A. Italiano2, R.G. Maki1, M.L. Keohan3
  • 1Department Of Medicine And Pediatrics, Mount Sinai School of Medicine, 10029-6574 - New York, NY/US
  • 2Medical Oncology, Institute Bergoni, FR-33076 - Bordeaux CEDEX/FR
  • 3Department Of Medicine - Melanoma And Sarcoma Service, Memorial Sloan Kettering Cancer Center, 10068 - New York/US



Data related to management and outcome of BM of sarcoma are scarce.


From 1991 to 2010, from over 4500 sarcoma pts treated at MSKCC, 107 developed BM.


Highest relative frequency came from ASPS (26%,7/27 pts), with an absolute number highest for LMS(37%). BM metachronous in 96 cases (90%). Median time between diagnosis of metastatic sarcoma and the diagnosis of BM was 9 months (range 5.5–12.5). Locoregional treatment (surgery ± RT) in 83 pts (78%). Systemic CT in 18 pts (17%) after diagnosis of BM. One PR (EWS) in 15 evaluable pts. One hundred-one pts died (94%), 6 still alive. Two living pts with follow-up >24 months had complete surgery of BM. Deaths related to BM progression were 54 (54%), related exclusively to systemic PD were 47 (46%). Median OS was 3.6 months (95% CI: 2.9-4.3). One-year OS rate was 16% (95% CI 9–23). On univariate analysis, histology, delay between the diagnosis of sarcoma and BM relapse, number of lesions, disease status and PS were significantly associated with OS. Surgery was significantly related to improved OS while RT was not. On multivariate analysis, time between diagnosis of sarcoma and BM relapse and disease status were pre-therapeutic prognostic factors associated with OS.


SARCOMA pts with BM have poor outcome. RT was not associated with improved survival. Long-term survival is achieved in small proportion of pts managed by surgery. CT had little activity after BM, consistent with the advanced nature of the pts' sarcomas.


All authors have declared no conflicts of interest.